Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|February 10, 2016
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's diseaseSatomi Watanabe, Masayuki Takeda, Takayuki Takahama, et al.
BMC Pulmonary Medicine|May 9, 2021
Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancerOsamu Nishiyama, Shigeki Shimizu, Koji Haratani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2026
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)Hiroaki Kanemura, Junko Tanizaki, Koji Matsumoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2017
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with NivolumabJunko Tanizaki, Koji Haratani, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2012
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancerJunko Tanizaki, Isamu Okamoto, Takafumi Okabe, et al.
Cancer Science|November 4, 2018
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancerSatomi Watanabe, Hidetoshi Hayashi, Koji Haratani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2021
KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i> <sup>G12C</sup> Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling MechanismsShinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, et al.
Therapeutic Advances in Medical Oncology|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancerShun Lu, Mariano Provencio Pulla, Eldsamira Mascarenhas, et al.
Cancer Science|March 20, 2015
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancerJunji Tsurutani, Katsumasa Kuroi, Tsutomu Iwasa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung CancerKeiichi Ota, Koichi Azuma, Akihiko Kawahara, et al.
Pageof 7